IncobotulinumtoxinA for Aesthetic Treatments: Review and Recommendations From Latin America-Reference-Cited by-同舟云学术

IncobotulinumtoxinA for Aesthetic Treatments: Review and Recommendations From Latin America

Published:2024-07-24 Issue:9S Volume:50 Page:S24-S34
ISSN:1076-0512
Container-title:Dermatologic Surgery
language:en
Short-container-title:Dermatol Surg

Author:

de Sanctis Pecora Carla¹,Trindade de Almeida Ada²,Figueredo Vinicius³,Hirano Cyro⁴,Bugallo Alejandra⁵,Cortés Cristina⁶,Welsh Esperanza C.⁷,Spada Julieta⁸,Heredia Nicolás⁹,de La Fuente Victoria¹⁰,Muniz Mariana¹¹

Affiliation:

1. Private Practice, Clínica Dermatologie, São Paulo, Brazil;

2. Private Practice and Hospital do Servidor Público Municipal de São Paulo, Brazil;

3. Private Practice, Vinicius Figueredo Dermatology, São Paulo, Brazil;

4. Private Practice, CD Clínica Dermatológica, Rio de Janeiro, Brazil;

5. Private Practice, Bugallo Centro de Estetica y Laser, Buenos Aires, Argentina;

6. Private Practice, Escuela de Medicina y Ciencias de la Salud del Tec de Monterrey, Monterrey, México;

7. Welsh Derm, Monterrey Private Office, Monterrey, Nuevo Leon, Mexico;

8. Private Practice, Spada Dermatología y Estética, Buenos Aires, Argentina;

9. Private Practice, Face and Nose Institute, Bogota, Colombia;

10. Private Practice, Levels High-End Dermatology Clinic, Ciudad de México, Mexico;

11. Private Practice, Mariana Muniz Dermatology, São Paulo, Brazil

Abstract

BACKGROUND As new aesthetic treatment techniques are developed, the understanding of botulinum toxin type A safety and treatment outcomes continues to evolve. OBJECTIVE This article was developed to provide a comprehensive up-to-date reference for clinicians using incobotulinumtoxinA (INCO; Xeomin/Bocouture, Merz Pharmaceuticals GmbH, Frankfurt, Germany) for aesthetic treatments. PATIENTS AND METHODS/MATERIALS A Latin American panel of 11 physicians was assembled to discuss and develop recommendations on the use of INCO for aesthetic treatment based on the literature review and their private medical practice. RESULTS The panel found that INCO is a highly purified botulinum toxin, without other clostridial proteins (hemagglutinins and nonhemagglutinins). IncobotulinumtoxinA has proven its efficacy and duration over time, maintaining response after multiple treatment cycles. CONCLUSION This recommendation provides up-to-date information on the use of INCO for aesthetic treatment, focusing on the differential properties of this product regarding its purity, performance, customization, and patient satisfaction.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference48 articles.

1. Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products;Frevert;Drugs R D,2015

2. Neurotoxin impurities: a review of threats to efficacy;Park;Plast Reconstr Surg Glob Open,2020

3. Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®;Frevert;Drugs R D,2010

4. IncobotulinumtoxinA in aesthetics: Russian multidisciplinary expert consensus recommendations;Yutskovskaya;Clin Cosmet Investig Dermatol,2015

5. Aesthetic applications of botulinum toxin A in Asians: an international, multidisciplinary, Pan-Asian consensus;Sundaram;Plast Reconstr Surg Glob Open,2016